TABLE 4.
Evaluation of in vivo efficacies in the GKO mouse modela
| Treatment (dose [mg/kg] or time point) | TAACF no. (MIC)b | Organ | Log CFU/organ (SD) | Log CFU decrease vs control |
|---|---|---|---|---|
| None (day 15) | Lung | 6.81 (±0.09) | ||
| Spleen | 5.37 (±0.18) | |||
| None (day 24) | Lung | 7.57 (±0.11) | ||
| Spleen | 6.57 (±0.17) | |||
| INH (25) | Lung | 4.47 (±0.12) | 3.10 | |
| Spleen | 2.20 (±0.45) | 4.37 | ||
| Compound 6 (300) | 115347 (0.39) | Lung | 7.64 | −0.06 |
| Spleen | 6.75 | −0.18 | ||
| Compound 7 (300) | 151985 (0.78) | Lung | 4.55 (±0.23) | 3.02 |
| Spleen | 3.95 (±0.10) | 2.62 | ||
| Compound 8 (300) | 149513 (0.39) | Lung | 8.73 | −0.68 |
| Spleen | 7.18 | −0.47 | ||
| Compound 9 (300) | 153731 (0.78) | Lung | 7.17 | 0.4 |
| Spleen | 6.63 | −0.016 | ||
| Compound 10 (300) | 150565 (0.10) | Lung | 7.41 | 0.16 |
| Spleen | 6.96 | −0.38 | ||
| Compound 11 (300) | 149514 (0.10) | Lung | 8.07 | −0.03 |
| Spleen | 7.17 | −0.46 | ||
| Compound 12 (300) | 153293 (0.10) | Lung | 7.21 | 0.36 |
| Spleen | 6.62 | −0.05 |
a
Results from experiment 1 are shown.
b
The MICs for M. tuberculosis strain Erdman (used in the in vivo efficacy testing) were determined for all compounds selected for in vivo efficacy testing and are given in parentheses.